TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
NorthX Biologics AB
Closing information (x1000 DKK)
| Closing information | 2023/12 | 2022/12 | 2021/12 |
| Turnover |
73,548
|
106,208
|
100,743 |
| Financial expenses |
142
|
527
|
314 |
| Earnings before taxes |
-49,539
|
-7,847
|
-23,150 |
| EBITDA |
-42,047
|
-2,897
|
-16,317 |
| Total assets |
241,266
|
184,707
|
161,022 |
| Current assets |
111,714
|
92,240
|
75,945 |
| Current liabilities |
210,079
|
179,428
|
159,464 |
| Equity capital |
31,187
|
5,279
|
1,558 |
| - share capital |
67
|
67
|
73 |
| Employees (average) |
145
|
129
|
124 |
Financial ratios
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Solvency |
12.9%
|
2.9%
|
1.0% |
| Turnover per employee |
507
|
823
|
812 |
| Profit as a percentage of turnover |
-67.4%
|
-7.4%
|
-23.0% |
| Return on assets (ROA) |
-20.5%
|
-4.0%
|
-14.2% |
| Current ratio |
53.2%
|
51.4%
|
47.6% |
| Return on equity (ROE) |
-158.8%
|
-148.6%
|
-1485.9% |
| Change turnover |
-33,207
|
13,625
|
35,619 |
| Change turnover % |
-31%
|
15%
|
55% |
| Chg. No. of employees |
16
|
5
|
20 |
| Chg. No. of employees % |
12%
|
4%
|
19% |
Total value of public sale
| Fiscal year | 2023/12 | 2022/12 | 2021/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.